Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia
- Authors
- Koh, Kwang Kon; Oh, Pyung Chun; Sakuma, Ichiro; Lee, Yonghee; Han, Seung Hwan; Shin, Eak Kyun
- Issue Date
- 15-Oct-2016
- Publisher
- ELSEVIER IRELAND LTD
- Keywords
- Omega-3 fatty acids; Fenofibrate; Insulin resistance; Hypertriglyceridemia
- Citation
- INTERNATIONAL JOURNAL OF CARDIOLOGY, v.221, pp.342 - 346
- Journal Title
- INTERNATIONAL JOURNAL OF CARDIOLOGY
- Volume
- 221
- Start Page
- 342
- End Page
- 346
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7798
- DOI
- 10.1016/j.ijcard.2016.07.038
- ISSN
- 0167-5273
- Abstract
- Background: Effects of omega-3 fatty acids (n - 3 FA) combined with fenofibrate are not yet investigated, compared with fenofibrate. Methods: This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched among groups. All patients were recommended to maintain a low fat diet. Fifty patients with hypertriglyceridemia in each group were given placebo, n - 3 FA 2 g + fenofibrate 160 mg (combination), or fenofibrate 160 mg, respectively daily for 2 months. Results: Placebo, combination, and fenofibrate significantly decreased triglycerides by 7%, 41% and 30%, respectively and triglycerides/HDL cholesterol ratio by 11%, 45% and 32%, respectively relative to baseline measurements (all P < 0.05 by paired t-test). When compared with placebo and fenofibrate, these with combination were significant (P < 0.001 by ANOVA). When compared with placebo, both combination and fenofibrate significantly decreased apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen (all P < 0.05 by ANOVA), however, there were no significant differences between combination and fenofibrate. When compared with placebo, both combination and fenofibrate significantly reduced insulin and glucose (both P < 0.05 by ANOVA), and improved insulin sensitivity (P = 0.005 by ANOVA). However, there were no significant differences between combination and fenofibrate. Conclusions: When compared with fenofibrate, combination significantly decreased triglycerides and triglycerides/HDL cholesterol ratio. Otherwise, combination and fenofibrate significantly reduced apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen to a similar extent. Also, combination and fenofibrate significantly improved insulin sensitivity to a similar extent by reducing insulin and glucose in patients with hypertriglyceridemia. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7798)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.